2020
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal 2020, 27: 883-894. PMID: 32716690, PMCID: PMC8023410, DOI: 10.1177/1352458520937282.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory AgentsDimethyl FumarateHumansImmunity, HumoralImmunosuppressive AgentsMultiple Sclerosis, Relapsing-RemittingNeoplasm Recurrence, LocalProspective StudiesConceptsDelayed-release dimethyl fumarateAbsolute lymphocyte countT cellsMedian absolute lymphocyte countEffector memory T cellsDimethyl fumarate treatmentPhase 3b studyTotal T cellsAdverse event ratesMemory T cellsProtective humoral immunityForms of MSDMF BIDLymphocyte subsetsAdverse eventsLymphocyte countTotal IgAImmune environmentImmunoglobulin levelsNaive CD4Sustained efficacyHumoral immunityFumarate treatmentSubclass levelsCount changes
2017
Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count
Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. Multiple Sclerosis Journal 2017, 24: 728-738. PMID: 28480794, PMCID: PMC5665729, DOI: 10.1177/1352458517707069.Peer-Reviewed Original ResearchConceptsAbsolute lymphocyte countDMF-treated patientsPeripheral blood mononuclear cellsDimethyl fumarateLymphocyte countPeptide stimulationLow absolute lymphocyte countFollicular T helper cellsDMF-induced lymphopeniaInvariant T (MAIT) cellsPro-inflammatory cytokinesT-cell phenotypeBlood mononuclear cellsT cell productionT helper cellsT lymphocyte functionMemory B cellsActivation-induced cell deathMultiparametric flow cytometryUntreated patientsMultiple sclerosisMononuclear cellsHealthy controlsT cellsT lymphocytes
2016
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity
Longbrake EE, Cross AH. Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity. JAMA Neurology 2016, 73: 1-7. PMID: 26720195, DOI: 10.1001/jamaneurol.2015.3977.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsB-LymphocytesCytokinesHumansImmunity, HumoralImmunosuppressive AgentsMultiple SclerosisRecurrenceConceptsDisease-modifying therapiesB cell immunityB cellsMultiple sclerosisAnti-inflammatory cytokine interleukin-10B-cell-depleting agentsMultiple Sclerosis Disease-Modifying TherapiesMost disease-modifying therapiesCytokine interleukin-10Memory B cellsB cell functionB-cell phenotypeB cell expressionB cell productionNaive B cellsMagnetic resonance imagingB cell precursorsClinical courseTherapeutic trialsInterleukin-10Proinflammatory cytokinesHumoral immunityClinical activityTherapeutic interventionsResonance imaging
2015
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Longbrake E, Ramsbottom M, Cantoni C, Ghezzi L, Cross A, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Multiple Sclerosis Journal 2015, 22: 1061-1070. PMID: 26459150, PMCID: PMC4829494, DOI: 10.1177/1352458515608961.Peer-Reviewed Original ResearchConceptsDMF-treated patientsMemory T cellsMultiple sclerosis patientsT cellsMS patientsDendritic cellsSclerosis patientsEffector memory T cellsUntreated MS patientsMyeloid dendritic cellsAbsolute lymphocyte countPlasmacytoid dendritic cellsNatural killer cellsNaïve T cellsMechanism of actionLymphocyte countLymphopenic patientsRegulatory cellsKiller cellsPeripheral bloodImmune cellsHealthy controlsPatientsB cellsFlow cytometry
2014
Dimethyl fumarate associated lymphopenia in clinical practice
Longbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Multiple Sclerosis Journal 2014, 21: 796-797. PMID: 25432948, PMCID: PMC4426020, DOI: 10.1177/1352458514559299.Peer-Reviewed Original Research
2013
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
Longbrake EE, Parks BJ, Cross AH. Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology And Neuroscience Reports 2013, 13: 390. PMID: 24027005, PMCID: PMC3967547, DOI: 10.1007/s11910-013-0390-z.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClinical Trials as TopicHumansImmunosuppressive AgentsMultiple Sclerosis